Follicular dendritic cell sarcoma (FDCS) is a very rare malignant tumor derived from follicular dendritic cells. Radical resection is the standard therapy for patients with local disease, but an optimal chemotherapy regimen has not been determined for unresectable disease. We report our experience of an FDCS patient with multiorgan involvement. In the present case, disease was only located in the pancreas initially and radical resection was performed. Multiple metastasis developed after the treatment and several factors that indicated a poor prognosis were observed.
1-4 Radical resection is the standard therapy for patients with local disease, and adjuvant radiotherapy did not have a significant influence on survival outcomes. 1, 5 Chemotherapy is indicated for patients with unresectable disease or multiorgan involvement. 1, 6 An optimal chemotherapy regimen has not been determined for this rare disease and cytotoxic agents for malignant lymphoma or soft tissue sarcoma are commonly used to treat FDCS patients. 4, 7, 8 Therefore, the accumulation of case reports is important to clarify the pathophysiology of FDCS and establish an optimal treatment strategy. We report our experience of an FDCS patient with multiorgan involvement whose disease was controlled by multiple chemotherapy regimens and who maintained a good performance status over a long period.
2 | CASE REPORT
| Clinical course
A 42-year-old Japanese woman initially complained of chest discomfort.
The patient was initially diagnosed with a solid pseudopapillary neoplasm However, a second course could not be initiated at day 22 because as diarrhea and loss of appetite. Although we attempted to recover the beneficial performance status of the treatment using intravenously administered saline to counter the dehydration caused by excessive diarrhea, disease progression continued, and we decided that a continuation of the chemotherapy was impossible.
| Laboratory data
CT scans were performed before progression, and we finally decided treatment change. However, in this case, changes in alkaline phosphatase (ALP) and C-reactive protein (CRP) looked associated with CT image, and we also used ALP and CRP as a possible surrogate marker to infer effectiveness of treatment. The relationship between disease control and laboratory data is shown in Figure 3 . During effective chemotherapy treatment with DXR, ESHAP, or PTX, CRP and ALP values were decreased or were maintained at the same level, and during disease progression, these values were increased significantly. After the first administration of bendamustine, CRP and ALP levels were significantly and rapidly decreased. However, adverse events related to bendamustine were prolonged, and we could not start a second cycle of chemotherapy on day 22 of the first cycle. On day 35 of the first cycle, ALP, lactate dehydrogenase, and CRP were significantly increased and disease progression was observed.
| DISCUSSION
In a pooled analysis of FDCS patients by Saygin et al, 1 68% of FDCS patients had extranodal disease, and a common extranodal site, including the liver, lung, tonsil, spleen, or soft tissue, was involved. FDCS of the pancreas as reported in the present case is very rare. In this analysis, they reported that early disease accounted for 85% of all FDCS cases. Because radical resection is indicated for most of FDCS patients,
there have been few reports of advanced disease, which is indicated for chemotherapy. In another case report, CHOP, which is the standard chemotherapy for malignant lymphoma and salvage therapy for refractory cases after the treatment of malignant lymphomas and soft tissue sarcomas, was indicated for unresectable patients. 6 Other studies reported that chemotherapy for malignant lymphoma or soft tissue sarcoma was commonly selected, but optimal palliative chemotherapy regimens are controversial and data on the use of palliative chemotherapy are limited for refractory FDCS.
To our knowledge, the control of disease in an FDCS patient using many different chemotherapy regimens to maintain a good performance status has not been reported previously. Saygin et al reported prognostic variables of FDCS patients from a pooled univariate analysis of all published data and indicated that age (young age ≤ 40 years), absence of lymphoplasmacytic infiltration, large tumor size (>6 cm), and mitotic counts (≥5/10 high-power field) were significant indicators of a poor prognosis. In multivariate analysis, lymphoplasmacytic infiltration and tumor size were associated with a poor prognosis.
Furthermore, the median survival for local disease was 168 months, and the 2-year survival rate was 82.8% for local disease. However, the 2-year survival rate was 42.8% for metastatic disease. 1 In the present case, disease was only located in the pancreas initially, and radical resection was performed, but disease-free survival was only 6 months.
In the current case study, multiple metastasis developed after the treatment, and several factors that indicated a poor prognosis were observed that were in accordance with a previous study by Saygin et al. The current case study had a very poor prognostic disease but survived for a long time with a good performance status because of the multiple chemotherapy treatments administered.
The characteristics of the clinical course of the present case were as follows: (i) although it was a very aggressive tumor and performance status was low before DXR, the tumor shrunk rapidly and the patient's performance status recovered immediately after the indication of DXR; (ii) the response to DXR was very good, and the reason for changing to another regimen was not due to progressive disease; nevertheless, IFM and CHOP (containing DXR) was not effective in treating the disease; (iii) although the use of the third-and the fourth-line chemotherapy, normally used to treat soft tissue sarcoma FIGURE 3 Relationship between changes in laboratory data (CRP and ALP) and tumor responses to chemotherapy and malignant lymphoma, was not effective, the fifth-line chemotherapy (ESHAP) and sixth-line PTX were effective and performance status recovered.
As far as we know, this is the first study reporting the indication of bendamustine for FDCS patients. Bendamustine is very effective for low-grade B-cell lymphoma and is a current standard chemotherapy for low-grade B-cell lymphoma. 16 In addition, clinical trials evaluating the use of bendamustine in diffuse large B-cell lymphoma, an intermediate grade lymphoma, are under way. The result of a phase II clinical trial to evaluate the effectiveness of bendamustine in previously treated diffuse large B-cell lymphoma reported that the overall response rate was 62.7%, the complete response rate was 37.3%, and the progression-free survival was 6.7 months. 17 Bendamustine is expected to become a key drug for the treatment of intermediate grade lymphoma. The result of a phase II clinical trial to evaluate the effectiveness of bendamustine in previously treated soft tissue sarcoma reported that the partial response rate was 3%, the stable disease rate was 31%, and the 3-month progression-free survival rate was 35.3% and 6-month progression-free survival rate was 23.5%. 
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